REHOVOT, Israel and BRIDGEWATER, N.J., June 18, 2014 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals (the "Company"), a clinical stage specialty pharmaceutical company focused on the development, patenting and commercialization of proprietary topical foams to address unmet needs in dermatology, today announced that Dov Tamarkin Ph.D., CEO, will present an update on the Company and its pipeline at the BIO International Convention (BIO 2014) on Thursday, June 26th in San Diego, CA.
|Date:||June 26th, 2014|
|Time:||11:30 a.m. PT|
|Location:||Solana Beach Room, San Diego Convention Center|
|Track:||BIO Business Forum|
Dr. Tamarkin will provide a review of the progress of Foamix's lead product candidates, FMX101 for moderate-to-severe acne, FMX102 for impetigo and other skin infections, and FDX104 for chemotherapy-induced rashes. FMX101 and FMX102 are based on Foamix's proprietary topical minocycline foam. A Phase II clinical trial of FMX101 involving moderate-to-severe acne patients showed a statistically significant reduction in inflammatory lesions after only three weeks of treatment, and the full therapeutic effect of an approximately 71% reduction in inflammatory lesions was reached after six weeks of treatment, with no systemic side effects. Dr. Tamarkin will further provide updates on the Company's strategy and development and licensing agreements.
About the 2014 BIO International Convention
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition - the BIO Exhibition. The 2014 BIO International Convention will take place from June 23rd - 26th 2014.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on the development of patented topical foams for dermatology. The Company's lead product, Minocycline Foam, is the first-ever topical minocycline that can be used for the treatment of acne, skin infections and rosacea. Minocycline is a well-known broad-spectrum oral antibiotic, which Foamix has uniquely transformed into a topically-applied, patented-form of the drug, thereby increasing efficacy, speed of action and minimizing side effects. The Company has successfully completed Phase II clinical trials in acne and impetigo using its patented foam delivery platform with minocycline. Besides these clinical stage drugs, Foamix has many pipeline drugs for dermatology and other indications using its unique topical minocycline or doxycycline and its patented delivery technologies in pre-clinical and pilot study stages.
As an IP and technology leader in topical drug development, including in foam and gel systems, Foamix has licensed foam products to pharmaceutical companies, such as Bayer, Merz and Actavis, that are at various stages of development including Phase II, Phase III clinical trials and pre-NDA stages.
To date, Foamix has 29 issued patents in the United States and 65 granted patents worldwide.
For additional information please see www.foamix.co.il
CONTACT: For more information, please contact: Dov Tamarkin, CEO, Foamix Pharmaceuticals Ltd. +972-8-9316233; firstname.lastname@example.org Dave Domzalski, President, Foamix Pharmaceuticals Inc. +1-800-775-7936; email@example.com Dorit Hayon, Business Development Manager, Foamix Pharmaceuticals Ltd. +972-8-9316233; firstname.lastname@example.org U.S. Investor Relations: Michael Rice LifeSci Advisors, LLC +1-646-597-6979; email@example.comSource:Foamix, Ltd.